Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Yihui Zhou,Xiaomeng Gao,Yuan Meng,Bo Yang,Qiaojun He,Ji Cao

DOI: https://doi.org/10.3389/fphar.2021.785732

IF: 5.6

2021-01-01

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2021.748852.].

What problem does this paper attempt to address?

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Ru Zhou,Mahboubeh Yazdanifar,Lopamudra Das Roy,Lynsey M. Whilding,Artemis Gavrill,John Maher,Pinku Mukherjee

DOI: https://doi.org/10.3389/fimmu.2020.628776

IF: 7.3

2020-12-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2019.01149.].

immunology
Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Jiaojiao Hao,Zhenglin Li,Changlin Zhang,Wendan Yu,Zhipeng Tang,Yixin Li,Xu Feng,Yue Gao,Quentin Liu,Wenlin Huang,Wei Guo,Wuguo Deng

DOI: https://doi.org/10.62347/suki5933

2024-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 13 in vol. 7, PMID: 28123844.].
Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Xing Bian,Xiaolin Wang,Qiuyan Zhang,Liying Ma,Guozhen Cao,Ao Xu,Jinhua Han,Jun Huang,Wenchu Lin

DOI: https://doi.org/10.3389/fonc.2023.1192526

IF: 4.7

2023-04-13

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.565820.].

oncology
Corrigendum: Multifunctions of CRIF1 in Cancers and Mitochondrial Dysfunction.

Yangzhou Jiang,Yang Xiang,Chuanchuan Lin,Weiwei Zhang,Zhenxing Yang,Lixin Xiang,Yanni Xiao,Li Chen,Qian Ran,Zhongjun Li

DOI: https://doi.org/10.3389/fonc.2023.1271492

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.1009948.].
Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Yueyun Pan,Yinda Yu,Xiaojian Wang,Ting Zhang

DOI: https://doi.org/10.3389/fimmu.2021.775758

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2020.583084.].
Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen,Gang Jia,Xilin Zhang,Wenxue Ma

DOI: https://doi.org/10.3389/fimmu.2024.1376045

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1332057.].

immunology
Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

Jun Cao,Mengdi Zhang,Bin Wang,Long Zhang,Fangfang Zhou,Meiyu Fang

DOI: https://doi.org/10.3389/fonc.2021.745052

IF: 4.7

2021-08-17

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.658552.].

oncology
Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Yi Qian,Meimei Zhao,Qinghua Han,Jingkang Wang,Lixi Liao,Heng Yang,Dan Liu,Pengfei Tu,Hong Liang,Kewu Zeng

DOI: https://doi.org/10.1016/j.apsb.2024.02.013

IF: 14.903

2024-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2021.01.011.].
Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Xin Tian,Lina Wu,Min Jiang,Zhenyong Zhang,Rong Wu,Jianing Miao,Caigang Liu,Song Gao

DOI: https://doi.org/10.3389/fonc.2022.793448

IF: 4.7

2022-04-06

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.641399.].

oncology
Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

DOI: https://doi.org/10.2147/IJN.S500182

2024-10-14

Abstract:[This corrects the article DOI: 10.2147/IJN.S448556.].
Corrigendum: Anticancer applications of phytochemicals in gastric cancer: effects and molecular mechanism

Zhaofeng Liang,Yumeng Xu,Yue Zhang,Xinyi Zhang,Jiajia Song,Hui Qian,Jianhua Jin

DOI: https://doi.org/10.3389/fphar.2024.1405513

2024-08-19

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.1078090.].
Corrigendum: Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer

Huijuan Liu,Honglian Tao,Hongqi Wang,Yuyan Yang,Ru Yang,Xintong Dai,Xiujuan Ding,Haidong Wu,Shuang Chen,Tao Sun

DOI: https://doi.org/10.3389/fonc.2022.830506

IF: 4.7

2022-02-24

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.619317.].

oncology
Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Wei Wang,Bo Hu,Jiang-Jiang Qin,Jianwen Cheng,Xin Li,Mehrdad Rajaei,Jia Fan,Xin-Rong Yang,Ruiwen Zhang

DOI: https://doi.org/10.1016/j.gendis.2019.12.006

IF: 7.376

2019-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2019.06.001.].
Corrigendum: CORO1C is Associated with Poor Prognosis and Promotes Metastasis Through PI3K/AKT Pathway in Colorectal Cancer

Zongxia Wang,Lizhou Jia,Yushu sun,Chunli Li,Lingli Zhang,Xiangcheng Wang,Hao Chen

DOI: https://doi.org/10.3389/fmolb.2021.727347

IF: 6.113

2021-08-30

Frontiers in Molecular Biosciences

Abstract:[This corrects the article DOI: 10.3389/fmolb.2021.682594.].

biochemistry & molecular biology
Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Xuan Wei,Juanjuan Shi,Qianhan Lin,Xiaoxue Ma,Yingxin Pang,Hongluan Mao,Rui Li,Wei Lu,Yu Wang,Peishu Liu

DOI: https://doi.org/10.3389/fonc.2021.742374

IF: 4.7

2021-09-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.642229.].

oncology
Corrigendum: Microbiome Crosstalk in Immunotherapy and Anti-Angiogenesis Therapy

Xueting Wan,Mengyao Song,Aiyun Wang,Yang Zhao,Zhonghong Wei,Yin Lu

DOI: https://doi.org/10.3389/fimmu.2022.887775

IF: 7.3

2022-04-21

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.747914.].

immunology
Corrigendum: Downregulation of HMGA1 Mediates Autophagy and Inhibits Migration and Invasion in Bladder Cancer via miRNA-221/TP53INP1/p-ERK Axis

Xiaoqiang Liu,Zhengtao Zhou,Yibing Wang,Ke Zhu,Wen Deng,Yulei Li,Xiaochen Zhou,Luyao Chen,Yu Li,An Xie,Tao Zeng,Gongxian Wang,Bin Fu

DOI: https://doi.org/10.3389/fonc.2020.01735

IF: 4.7

2020-09-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.00589.].

oncology
Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

Xiaozhong Liao,Ying Gao,Jiahui Liu,Lan-Ting Tao,Dongmei Wang,Dan Xie,Sui‐Lin Mo

DOI: https://doi.org/10.3389/fonc.2021.670798

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.01756/full.].
Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]

Wan-Xin Peng,Fei Liu,Jia-Hong Jiang,Hang Yuan,Ziqiang Zhang,Liu Yang,Yin-Yuan Mo

DOI: https://doi.org/10.1016/j.gendis.2024.101352

2024-06-15

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2022.02.014.].
Corrigendum: Negatively Regulated by Mir-29C-3p, MTFR1 Promotes the Progression and Glycolysis in Lung Adenocarcinoma Via the AMPK/mTOR Signalling Pathway.

Yongmeng Li,Yanfei Liu,Kai Jin,Rui Dong,Cun Gao,Libo Si,Zitong Feng,Huiying Zhang,Hui Tian

DOI: https://doi.org/10.3389/fcell.2022.870313

IF: 5.5

2022-01-01

Frontiers in Cell and Developmental Biology

Abstract:[This corrects the article DOI: 10.3389/fcell.2021.771824.].

Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Corrigendum: Multifunctions of CRIF1 in Cancers and Mitochondrial Dysfunction.

Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

Corrigendum: Anticancer applications of phytochemicals in gastric cancer: effects and molecular mechanism

Corrigendum: Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Corrigendum: CORO1C is Associated with Poor Prognosis and Promotes Metastasis Through PI3K/AKT Pathway in Colorectal Cancer

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Corrigendum: Microbiome Crosstalk in Immunotherapy and Anti-Angiogenesis Therapy

Corrigendum: Downregulation of HMGA1 Mediates Autophagy and Inhibits Migration and Invasion in Bladder Cancer via miRNA-221/TP53INP1/p-ERK Axis

Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]

Corrigendum: Negatively Regulated by Mir-29C-3p, MTFR1 Promotes the Progression and Glycolysis in Lung Adenocarcinoma Via the AMPK/mTOR Signalling Pathway.